BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Applied Data Research Release: Emerging Targets and Therapeutic Approaches Driving Activity in Autoimmune Disease Therapeutics


2/18/2008 7:28:48 AM

(Nashua, NH) – Autoimmune diseases can be considered one of the silent tragedies of human suffering. Leading a group of ailments that includes migraine, dementia, and depression, autoimmune conditions cause daily anguish for a significant portion of the population and yet remain underserved by the medical establishment and the healthcare community. The refractory nature of this family of diseases is routed in the complexities and genetic underpinnings of the human immune response, resulting in a set of disease targets that are at once physiologically ubiquitous and highly individualized.

Until recently, autoimmune disease patients were given little hope for effective treatment. But the convergence of improved elucidation of autoimmune disease mechanisms and the ability to design and manufacture recombinant proteins capable of attenuating the immune system cascade has led to systemic treatments that have demonstrated the ability to provide some degree of relief from autoimmune symptoms in a significant number of patients.

This sector is positioned for rapid growth. Biological drugs for multiple sclerosis, a group led by Biogen Idec’s Avonex, had a worldwide value of $5.6 billion in 2006, an increase of just under14% from the previous year. Biologicals indicated for rheumatoid arthritis, psoriasis and associated diseases reached $7.9 billion worldwide in 2006, a year-to-year increase of 19%. A number of potentially important pipeline drugs hold the promise of future improvements in patient outcomes. These developments are examined in a new and comprehensive report – Autoimmune Disease Therapeutics: Targets, Technologies and

Therapies. The report analyzes current autoimmune therapeutics and assesses the next generation of candidates and their probable impact on treatment options and the competitive landscape.

More information is available at www.applieddata.org .

About Applied Data

Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.

Contact: Greg Stone Voice: 603-595-6225 Fax: 603-804-0466 www.applieddata.org

Source: Applied Data Research



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES